JP2017501137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501137A5 JP2017501137A5 JP2016535646A JP2016535646A JP2017501137A5 JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5 JP 2016535646 A JP2016535646 A JP 2016535646A JP 2016535646 A JP2016535646 A JP 2016535646A JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- biomarker
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910663P | 2013-12-02 | 2013-12-02 | |
| US61/910,663 | 2013-12-02 | ||
| US201461975339P | 2014-04-04 | 2014-04-04 | |
| US61/975,339 | 2014-04-04 | ||
| PCT/US2014/068097 WO2015084808A1 (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501137A JP2017501137A (ja) | 2017-01-12 |
| JP2017501137A5 true JP2017501137A5 (enExample) | 2018-01-18 |
Family
ID=53274023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535646A Pending JP2017501137A (ja) | 2013-12-02 | 2014-12-02 | Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3077546A4 (enExample) |
| JP (1) | JP2017501137A (enExample) |
| CN (1) | CN105829547A (enExample) |
| AU (1) | AU2014357354A1 (enExample) |
| CA (1) | CA2931975A1 (enExample) |
| HK (1) | HK1223657A1 (enExample) |
| MX (1) | MX2016007066A (enExample) |
| TW (1) | TW201610168A (enExample) |
| WO (1) | WO2015084808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US20180223372A1 (en) * | 2015-08-03 | 2018-08-09 | Oncomed Pharmaceutical, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| MX2018003179A (es) * | 2015-09-16 | 2018-08-21 | Tobira Therapeutics Inc | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. |
| WO2018081437A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CN106990245B (zh) * | 2017-04-05 | 2018-07-31 | 东南大学 | 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110835372B (zh) * | 2019-11-06 | 2020-12-01 | 上海健康医学院 | 一种靶向Frizzled7单克隆抗体及其制备方法与应用 |
| JP7593584B2 (ja) * | 2020-03-10 | 2024-12-03 | 学校法人杏林学園 | 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN115337400A (zh) * | 2021-05-13 | 2022-11-15 | 中国科学院分子细胞科学卓越创新中心 | 诊断和治疗肿瘤的试剂及其用途 |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| WO2023113013A1 (ja) * | 2021-12-17 | 2023-06-22 | 国立大学法人京都大学 | 疾患発症の可能性の推定を行う遺伝子の選別方法及び疾患発症の可能性を推定する方法 |
| WO2024189200A1 (en) * | 2023-03-15 | 2024-09-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Cancer stratification and treatment |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO2001002568A2 (en) * | 1999-07-02 | 2001-01-11 | Chiron Corporation | Human genes and gene expression products |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20040247593A1 (en) * | 2002-10-04 | 2004-12-09 | Regents Of The University Of California, | Methods for treating cancer by inhibiting Wnt signaling |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| EP1685161A1 (en) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ion exchange-chromatography for purifying antibodies |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7947277B2 (en) | 2006-09-08 | 2011-05-24 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders |
| EP2084296B1 (en) * | 2006-09-29 | 2015-08-05 | Agendia N.V. | High-throughput diagnostic testing using arrays |
| CA2664738C (en) | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| ES2663536T3 (es) * | 2008-09-26 | 2018-04-13 | Oncomed Pharmaceuticals, Inc. | Agentes que se unen a receptores frizzled y usos de los mismos |
| US20100169025A1 (en) * | 2008-10-10 | 2010-07-01 | Arthur William T | Methods and gene expression signature for wnt/b-catenin signaling pathway |
| WO2010101793A2 (en) * | 2009-03-06 | 2010-09-10 | University Of South Alabama | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| AU2011205409B2 (en) | 2010-01-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Wnt-binding agents and uses thereof |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
-
2014
- 2014-12-02 HK HK16111927.7A patent/HK1223657A1/zh unknown
- 2014-12-02 CA CA2931975A patent/CA2931975A1/en not_active Abandoned
- 2014-12-02 EP EP14867583.8A patent/EP3077546A4/en not_active Withdrawn
- 2014-12-02 CN CN201480065718.7A patent/CN105829547A/zh active Pending
- 2014-12-02 AU AU2014357354A patent/AU2014357354A1/en not_active Abandoned
- 2014-12-02 JP JP2016535646A patent/JP2017501137A/ja active Pending
- 2014-12-02 TW TW103141799A patent/TW201610168A/zh unknown
- 2014-12-02 MX MX2016007066A patent/MX2016007066A/es unknown
- 2014-12-02 WO PCT/US2014/068097 patent/WO2015084808A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501137A5 (enExample) | ||
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| JP2016520289A5 (enExample) | ||
| JP6781184B2 (ja) | がん転移の予後診断および処置のための方法 | |
| JP7032329B2 (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| JP2015529641A5 (enExample) | ||
| JP2016533395A5 (enExample) | ||
| JP2017517507A5 (enExample) | ||
| JP2008523073A5 (enExample) | ||
| KR20160048196A (ko) | 교모세포종의 치료를 위한 진단 방법 및 조성물 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| RU2016147398A (ru) | Способы оценивания и лечения острого миелоидного лейкоза | |
| WO2014151606A4 (en) | Methods of treating pancreatic cancer | |
| JP2019523641A5 (enExample) | ||
| JP2018525994A5 (enExample) | ||
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| JP2015530868A5 (enExample) | ||
| RU2018104570A (ru) | Экспрессия fgfr и чувствительность к ингибитору fgfr | |
| JP2015210268A5 (enExample) | ||
| JP2017527533A5 (enExample) | ||
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| JP2015514712A5 (ja) | 発癌物質によって誘発される癌の治療における使用のためのｃｕｒａｘｉｎ | |
| Aieta et al. | Monitoring and characterization of circulating tumor cells (CTCs) in a patient with EML4-ALK–Positive Non–Small cell lung cancer (NSCLC) | |
| CN112739826A (zh) | 抗体-药物缀合物的敏感性标志物 |